TUTeresa Guerrero Urbano

Teresa Guerrero Urbano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Teresa Guerrero Urbano has a total of 341 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    RT-HaND-C: A Multi-Source, Validated Real-World Head and Neck Cancer Dataset for Research

    by Tom Young, Haleema Drake, Victoria Butterworth, Wulaningsih Wahyu, Bill Dann, Aga Giemza, Eleanor Ivy, Delali Adjogatse, Khrishanthne Sambasivan, Imran Petkar, et al.


  • Open Access

    Data-centric artificial intelligence and cancer research: construction of a real-world head and neck treatment data repository

    by V. Butterworth, T. Young, H. Drake, I. Palmer, T. Avgoulea, E. Ivy, J. Andriolo, C. Creppy, C. Routledge, D. Adjogatse, et al.


  • Open Access

    Real-world performance evaluation of commercial autocontouring software for head and neck cancer radiotherapy

    by Tom Young, Victoria Butterworth, Sarah Misson, Delali Adjogatse, Anthony Kong, Imran Petkar, Miguel Reis Ferreira, Mary Lei, Andrew King, Teresa Guerrero Urbano

    Objectives: To comprehensively evaluate the ability of ART-Plan (autocontouring software using artificial intelligence [AI]) to contour head and neck cancer (HNC) radiotherapy structures (organs-at-risk and elective nodal volumes) in a real-world setting, as required by NICE guidelines. Methods: Retrospective evaluation (n = 60) compared clinically used contours to AI-contours, using volumetric dice similarity coefficient (VDSC) and blinded radiation oncologist (RO) contour preference assessment. AI-contours were then generated prospectively for HNC radiotherapy patients (n = 61), before review by ROs. ROs recorded qualitative scoring and review/editing time. Geometric and dosimetric comparison of AI-contours and final contours was undertaken. Correlation coefficients between all metrics were calculated. Results: Retrospective median VDSC varied widely for different structures (0.23-0.88). 31.4% blinded contour assessments preferred clinician-generated contours, 32.9% preferred AI-generated contours, 35.7% saw no significant difference. Prospective evaluation showed AI-contour yielded significant time-saving in reviewing/editing for all structures compared to manual contouring. Qualitative scores demonstrated most structures had median scoring ≥4 (indicating no editing required). Geometric metrics showed high similarity for all structures except larynx. Dosimetric evaluation demonstrated clinically significant dose differences for larynx and elective nodal volumes. Strong correlation was seen between qualitative scoring and all geometric metrics. Conclusions: AI-contours showed excellent qualitative performance and facilitated time-saving. Protocol differences exist between commercial AI-solutions and implementing centres. Ongoing final clinician review of AI-contours remains essential. Advances in knowledge: This is the first study demonstrating ART-Plan’s capability for excellent qualitative ratings and significant time-savings for HNC radiotherapy contouring in a real-world workflow setting. 5-point Likert-scale qualitative scoring correlates strongly with geometric metrics.


  • Open Access

    RT-HaND-C: A Multi-Source, Validated Real-World Head and Neck Cancer Dataset for Research

    by Thomas Young, Haleema Drake, Victoria Butterworth, Wulaningsih Wahyu, Bill Dann, Aga Giemza, Eleanor Ivy, Delali Adjogatse, Khrishanthne Sambasivan, Imran Petkar, et al.

    Background Real-world data (RWD) is essential in head and neck cancer (HNC) research, offering insights into outcomes among diverse, comorbid patients often underrepresented in clinical trials. Methods We developed RT-HaND-C, a multi-source clinical dataset integrating structured EHR data, unstructured data extracted using an AI-driven NLP tool, and previously manually-curated datasets, with extensive demographic, disease, laboratory, treatment, outcome and radiotherapy dosimetry data for all HNC oncology patients seen at our centre (2010–2023). The dataset underwent rigorous evaluation for accuracy, completeness, consistency, and usability. Results The retrospective cohort comprises 2,895 HNC patients with over 1.8 million data points across over 2000 data categories. Accuracy assessments exceeded 98% for most variables. An example of usability testing showing rapid extraction and evaluation of longitudinal weight patterns post-radical radiotherapy is depicted. Conclusions RT-HaND-C represents a novel, high-quality RWD resource and evaluation framework. The dataset is available for research and collaboration, with ongoing efforts to enhance completeness and support prospective updates.

  • Externally validated digital decision support tool for time-to-osteoradionecrosis risk-stratification using right-censored multi-institutional observational cohorts

    by Laia Humbert-Vidan, Serageldin Kamel, Andrew Wentzel, Zaphanlene Kaffey, Moamen Abdelaal, Kyle B. Spier, Natalie A. West, G.ELisabeta Marai, Guadalupe Canahuate, Xinhua Zhang, et al.


  • Open Access

    Data-centric Artificial Intelligence and Cancer Research: Construction of a Real-World Head and Neck Treatment Data Repository

    by Victoria Butterworth, Tom Young, Haleema Drake, Isabel Palmer, Tania Avgoulea, Eleanor Ivy, Joshua Andriolo, Carole Creppy, Corla Routledge, Delali Adjogatse, et al.

    Background and Purpose The performance and generalisability of machine learning (ML) models relies on high-quality data. Retrospective and prospective collection of high-quality data for research use whilst respecting data protection and patient privacy remains a challenge in the clinical environment. Currently, months of laborious extraction and clinical annotation are often necessary before data analysis can begin. We present a novel institutional federated data lake, utilising open-source software, to facilitate efficient production of ML models from Head and Neck Cancer (HNC) imaging and Radiotherapy (RT) data. This structured pipeline dramatically reduces the time associated with the production of ML models and real-world evidence generation. This paper describes our governance-compliant processes and provides a framework for establishing similar databases. Materials and Methods XNAT, is a powerful open-source imaging platform. Within our department, it forms a part of the local secure enclave for the purposes of federated learning in artificial intelligence projects and provides import, archiving, processing, search and secure distribution facilities for imaging and RT data. Results We have created a clinically annotated, carefully curated, data lake of 2,895 consenting HNC patients containing 22,170 relevant diagnostic, staging, treatment and monitoring imaging sets. Key recommendations for replication include infrastructure planning, robust patient and data selection criteria and prioritising patient consent and privacy. Conclusions This secure and extensible imaging and HNC RT cancer database set-up promises to be an exceedingly useful tool for research, revolutionising the time and cost associated with the production of ML models, making the process safer, faster and more efficient. Highlights Real-world data is critical for building predictive clinical models. Curation of clinical data for machine learning can necessitate months of laborious extraction and annotation. Patients have the right to have their data handled with the highest standards of respect, security and governance. We describe a database infrastructure constructed under a transparent and safe system of control and stewardship. This secure and extensible structured database dramatically reduces data extraction time for AI-driven cancer research.

  • Open Access

    Multi-institutional Normal Tissue Complication Probability (NTCP) Prediction Model for Mandibular Osteoradionecrosis: Results from the PREDMORN Study

    by Laia Humbert-Vidan, Christian R. Hansen, Steven Petit, Carles Muñoz-Montplet, Abdallah S. R. Mohamed, Deborah P. Saunders, Vinod Patel, Gerda M. Verduijni, Wilma D. Heemsbergen, Arjen van der Schaaf, et al.

    Background Mandibular osteoradionecrosis (ORN) is a severe late complication affecting patients with head and neck cancer (HNC) treated with radiotherapy that significantly impacts patients’ quality of life and can require costly interventions. While radiation dose is a key factor, other clinical and demographic risk factors influence ORN development. Previous predictive models have primarily been single-institutional, limiting their generalizability. The PREDMORN Consortium was established to address these limitations. In this first analysis, we have aimed to reproduce existing statistical association and modelling analyses on the largest and most diverse mandibular ORN cohort worldwide to allow comparison with previous studies. As such, we have developed, tested and externally validated a multi-institutional normal tissue complication probability (NTCP) model for mandibular ORN. Methods This retrospective multi-institutional study included 1,184 HNC patients (389 ORN cases) from seven institutions. Clinical, demographic, and dosimetric (DVH) variables were analysed to develop a prediction model (any grade of ORN vs. no ORN) using forward stepwise logistic regression with correlation-based variable pre-selection. The ORN NTCP model was developed on 80% of data from six institutions, tested on the remaining unseen 20%, and externally validated on the seventh institution’s dataset. Results Key predictors of ORN were D30%, V70Gy, pre-RT dental extractions, and smoking status. The ORN NTCP model demonstrated good calibration and predictive performance, with AUCs of 0.69 for internal testing and external validation, which improved when tested on a sub-cohort of oropharyngeal and locally advanced larynx/hypopharynx cancer cases (AUCs of 0.75). Conclusion The PREDMORN NTCP model is the largest multi-institutional effort to predict ORN risk in HNC patients. We provide guidance on how to adjust the NTCP predicted probabilities for differences in target population baseline ORN risk to facilitate application of the model. Future research will focus on incorporating imaging-based spatial data and further external validation to enhance clinical applicability.


  • Open Access

    Correlation of the treatment sensitivity of patient-derived organoids with treatment outcomes in patients with head and neck cancer (SOTO): protocol for a prospective observational study

    by Ifigenia Vasiliadou, Christiana Cattaneo, Phoebe Yuen Ka Chan, Rhonda Henley-Smith, Harry Gregson-Williams, Lisette Collins, Gabriella Wojewodka, Teresa Guerrero-Urbano, Jean-Pierre Jeannon, Steve Connor, et al.

    Introduction Organoids have been successfully used in several areas of cancer research and large living biobanks of patient-derived organoids (PDOs) have been developed from various malignancies. The characteristics of the original tumour tissue such as mutation signatures, phenotype and genetic diversity are well preserved in organoids, thus showing promising results for the use of this model in translational research. In this study, we aim to assess whether we can generate PDOs from head and neck squamous cell carcinoma (HNSCC) samples and whether PDOs can be used to predict treatment sensitivity in HNSCC patients as well as to explore potential biomarkers. Methods and analysis This is a prospective observational study at a single centre (Guy’s and St Thomas’ NHS Foundation Trust) to generate PDOs from patients’ samples to assess treatment response and to correlate with patients’ treatment outcomes. Patients will be included if they are diagnosed with HNSCC undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers and they will be categorised into three groups (cohort 1: primary surgery, cohort 2: primary radiotherapy and cohort 3: recurrent/metastatic disease). Research tumour samples will be collected and processed into PDOs and chemosensitivity/radiosensitivity will be assessed using established methods. Moreover, blood and other biological samples (eg, saliva) will be collected at different time intervals during treatment and will be processed in the laboratory for plasma and peripheral blood mononuclear cell (PBMC) isolation. Plasma and saliva will be used for circulating tumour DNA analysis and PBMC will be stored for assessment of the peripheral immune characteristics of the patients as well as to perform co-culture experiments with PDOs. SOTO study (correlation of the treatment Sensitivity of patient-derived Organoids with Treatment Outcomes in patients with head and neck cancer) uses the collaboration of several specialties in head and neck cancer and has the potential to explore multiple areas of research with the aim of offering a valid and effective approach to personalised medicine for cancer patients. Ethics and dissemination This study was approved by North West-Greater Manchester South Research Ethics Committee (REC Ref: 22/NW/0023) on 21 March 2022. An informed consent will be obtained from all participants prior to inclusion in the study. Results will be disseminated via peer-reviewed publications and presentations at international conferences. Trial registration number NCT05400239.


  • Fully automated radiotherapy treatment planning: A scan to plan challenge

    by Mark J. Gooding, Shafak Aluwini, Teresa Guerrero Urbano, Yasmin McQuinlan, Deborah Om, Floor H.E. Staal, Tanguy Perennec, Sana Azzarouali, Carlos E. Cardenas, Antony Carver, et al.


  • Open Access

    Mandibular dose-volume predicts time-to-osteoradionecrosis in an actuarial normal-tissue complication probability (NTCP) model: External validation of right-censored clinico-dosimetric and competing risk application across international multi-institutional observational cohorts and online graphical user interface clinical support tool assessment

    by Anderson Head, Neck Symptom Working Group, Laia Humbert-Vidan, Serageldin Kamel, Andrew Wentzel, Zaphanlene Kaffey, Moamen Abdelaal, Kyle B. Spier, Natalie A. West, G. Elisabeta Marai, et al.

    Background Existing studies on osteoradionecrosis of the jaw (ORNJ) have primarily used cross-sectional data, assessing risk factors at a single time point. Determining the time-to-event profile of ORNJ has important implications to monitor oral health in head and neck cancer (HNC) long-term survivors. Methods Demographic, clinical and dosimetric data were retrospectively obtained for a clinical observational cohort of 1129 patients with HNC treated with radiotherapy (RT) at The University of Texas MD Anderson Cancer Center. ORNJ was diagnosed in 198 patients (18%). A multivariable logistic regression analysis with forward stepwise variable selection identified significant predictors for ORNJ. These predictors were then used to train a Weibull Accelerated Failure Time (AFT) model, which was externally validated using an independent cohort of 265 patients (92 ORNJ cases and 173 controls) treated at Guy’s and St. Thomas’ Hospitals. Findings Our model identified that each unit increase in D25% is significantly associated with a 12% shorter time to ORNJ (Adjusted Time Ratio [ATR] 0·88, pInterpretation This study is the first to demonstrate a direct relationship between radiation dose and the time to ORNJ onset, providing a novel characterization of the impact of delivered dose not only on the probability of a late effect (ORNJ), but the conditional risk during survivorship. Funding This work was supported by various funding sources including NIH, NIDCR, NCI, NAPT, NASA, BCM, Affirmed Pharma, CRUK, KWF Dutch Cancer Society, NWO ZonMw, and the Apache Corporation.